Unknown statusInterventionalPhase 2Last updated Feb 10, 2015

Melatonin for Nocturia in Parkinson's Disease

Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease

Overview

ClinicalTrials.gov ID: NCT02359448
Lead Sponsor: University College, LondonOTHER
Brief Summary: This is an an open label clinical trial of sustained-release Melatonin 2mg once daily for 12 weeks in patients with Parkinsons's Disease reporting nocturia, defined as getting up regularly at night > twice to pass urine. The primary objective of this study is to evaluate the effects of exogenous melatonin on bother related to nocturia. Secondary objectives are to evaluate: 1) Mean night time urinary frequency 2)Volume of urine voided at night 3)Incontinence and other lower urinary tract symptoms (LUTS) 3)Quality of sleep 4) Quality of life 5) Sleep disturbance of partners 6)Safety

Status

Overall Status: Unknown status
Start Date: Apr 2015
Primary Completion Date: Sep 2015Estimated
Completion Date: Dec 2015Estimated

Study Record Dates

First Submitted: Feb 4, 2015
First Submitted that Met QC Criteria: Feb 4, 2015
First Posted: Feb 10, 2015Estimated
Last Update Submitted that Met QC Criteria: Feb 4, 2015
Last Update Posted: Feb 10, 2015Estimated
Last Verified: Feb 2015

NCT02768077Unknown status

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

NCT03258294Unknown status

Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease

NCT01575678Unknown status

The Effect of Melatonin on Nocturnal Enuresis

NCT02631148Terminated

Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.

NCT00397189Completed

Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients

NCT04287543Withdrawn

Melatonin on Clock Genes in Parkinson's Disease